JP2016518358A - ポリプレックス - Google Patents

ポリプレックス Download PDF

Info

Publication number
JP2016518358A
JP2016518358A JP2016507694A JP2016507694A JP2016518358A JP 2016518358 A JP2016518358 A JP 2016518358A JP 2016507694 A JP2016507694 A JP 2016507694A JP 2016507694 A JP2016507694 A JP 2016507694A JP 2016518358 A JP2016518358 A JP 2016518358A
Authority
JP
Japan
Prior art keywords
mk2i
peptide
composition
polymer
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518358A5 (enExample
Inventor
デュヴァル，クレイグ
コナー エヴァンス，ブライアン
コナー エヴァンス，ブライアン
ブロフィー，コリーン
ホッキング，カイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2016518358A publication Critical patent/JP2016518358A/ja
Publication of JP2016518358A5 publication Critical patent/JP2016518358A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
JP2016507694A 2013-04-11 2014-04-11 ポリプレックス Pending JP2016518358A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811078P 2013-04-11 2013-04-11
US61/811,078 2013-04-11
PCT/US2014/033873 WO2014169256A2 (en) 2013-04-11 2014-04-11 Polyplexes

Publications (2)

Publication Number Publication Date
JP2016518358A true JP2016518358A (ja) 2016-06-23
JP2016518358A5 JP2016518358A5 (enExample) 2017-05-25

Family

ID=51690135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507694A Pending JP2016518358A (ja) 2013-04-11 2014-04-11 ポリプレックス

Country Status (12)

Country Link
US (1) US10835549B2 (enExample)
EP (1) EP2991616A4 (enExample)
JP (1) JP2016518358A (enExample)
KR (1) KR20150143639A (enExample)
CN (1) CN105431134A (enExample)
AU (1) AU2014250830A1 (enExample)
BR (1) BR112015025968A2 (enExample)
CA (1) CA2911315A1 (enExample)
HK (1) HK1216152A1 (enExample)
MX (1) MX2015014354A (enExample)
RU (1) RU2015148055A (enExample)
WO (1) WO2014169256A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
CN104815333B (zh) * 2015-04-05 2017-10-31 北京工业大学 一种聚离子胶束纳米粒子的制备方法及其应用
US11147827B2 (en) 2016-08-05 2021-10-19 Vanderbilt University Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
WO2003070823A2 (en) * 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
US9271933B2 (en) * 2007-11-27 2016-03-01 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
US20110060123A1 (en) * 2008-04-30 2011-03-10 Kazunori Kataoka Charge conversional ternary polyplex
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
CA2744104C (en) * 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOPHYSICAL CHEMISTRY, vol. 119, JPN7018000293, 2008, pages 303 - 306, ISSN: 0003731209 *
J CONTROL RELEASE, vol. 134, JPN7018000292, 2009, pages 47 - 54, ISSN: 0003731208 *
J CONTROL RELEASE, vol. 61, JPN6018003262, 1999, pages 137 - 143, ISSN: 0003731211 *
J PHYS CHEM B, vol. 116, JPN6018003261, 2012, pages 2356 - 2364, ISSN: 0003731210 *

Also Published As

Publication number Publication date
RU2015148055A (ru) 2017-05-16
US20160058876A1 (en) 2016-03-03
CA2911315A1 (en) 2014-10-16
EP2991616A2 (en) 2016-03-09
WO2014169256A2 (en) 2014-10-16
KR20150143639A (ko) 2015-12-23
BR112015025968A2 (pt) 2018-01-09
EP2991616A4 (en) 2016-11-09
AU2014250830A1 (en) 2015-11-12
HK1216152A1 (zh) 2016-10-21
US10835549B2 (en) 2020-11-17
CN105431134A (zh) 2016-03-23
MX2015014354A (es) 2016-06-07
WO2014169256A3 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
Zhao et al. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine (R15) triblock copolymer for siRNA delivery
Schellinger et al. Melittin-grafted HPMA-oligolysine based copolymers for gene delivery
Wang et al. Lacritin-mediated regeneration of the corneal epithelia by protein polymer nanoparticles
JP2008526749A (ja) 自己アセンブリするペプチドナノファイバーを用いたｐｄｇｆの徐放性の送達
US9765329B2 (en) Adipocyte-targeting non-viral gene delivery system
Luo et al. Acid-activated melittin for targeted and safe antitumor therapy
US9566347B2 (en) Peptides and methods using same
US20190248956A1 (en) Poly(l-lysine isolphthalamide) (plp) polymers with hydrophobic pendant chains
WO2019028469A1 (en) FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
AU2016205125A1 (en) Formulation of MK2 inhibitor peptides
US10835549B2 (en) Polyplexes
Ji et al. Dual Functioned Hexapeptide‐Coated Lipid‐Core Nanomicelles Suppress Toll‐Like Receptor‐Mediated Inflammatory Responses through Endotoxin Scavenging and Endosomal pH Modulation
Meng et al. Antibacterial coatings of biomedical surfaces by polydextran aldehyde/polyethylenimine nanofibers
US20240197896A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
Baoum et al. Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery
Bang et al. Targeted delivery of self-assembled nanocomplex between fusion peptides and siRNAs for breast cancer treatment
Rose et al. Gelatin coating to stabilize the transfection ability of nucleic acid polyplexes
Okada Targeted siRNA therapy using cytoplasm-responsive nanocarriers and cell-penetrating peptides
US8425900B2 (en) Method of delivering a protein into a cell
Pang et al. Enzyme-triggered polyelectrolyte complex for broad-spectrum antifungal therapy and biofilm eradication
Qian et al. Cationic Polypeptide Dendrimers with Concurrent Antibacterial and Anticancer Activities Depending on Topological Structure
US20210236584A1 (en) Compositions and methods for treating nervous system injuries
Evans Development of pH-responsive nano-polyplexes for intracellular delivery of therapeutic biomacromolecules
Wei et al. Antimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide
Mumcuoğlu Self-assembled peptide nanostructure delivery sytems for oligonucleotide therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180905